A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 535 participants.

Also called NCT01455870

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 535 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01455870
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Croatia, Denmark, Germany, Latvia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01455870. Randomized; quadruple masking; primary purpose treatment. Start 2013-05 (registry gives no type); primary completion 2015-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes
Intervention (Drug)
ITCA 650 60 mcg/day
Intervention (Drug)
sitagliptin
Lead sponsor
Intarcia Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct01455870
Content hash
b9f0c036db9da03dfbc17b391abc1925f8e453982dee7c71100c77aaeb84850b